05:18 PM EDT, 06/26/2024 (MT Newswires) -- 2seventy bio (TSVT) said late Wednesday it has sold its Hemophilia A program and rights to its in-vivo gene-editing technology outside of oncology and gene-editing for autologous or allogeneic cell therapies of immune cells to treat autoimmune disease to Novo Nordisk ( NVO ) .

2seventy said it will potentially receive up to $40 million in payments. The divestiture will include the transfer of the company's megaTAL technology and a license to underlying intellectual property, it said.

2seventy said it will focus exclusively on the commercialization and continued development of its Abecma therapy for multiple myeloma in collaboration with Bristol-Myers Squibb ( BMY )

2seventy shares were up nearly 8% in after-hours activity, while Novo Nordisk ( NVO ) rose 0.2%.

Price: 3.8800, Change: +0.28, Percent Change: +7.78